Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220940285> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W4220940285 abstract "Objective Severe insulin resistance syndromes, such as lipodystrophy, lead to diabetes, which is challenging to control. This study explored the safety and efficacy of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in a series of 12 patients with severe insulin resistance due to partial lipodystrophy. Methods A retrospective chart review of the safety (N = 22) and efficacy (N = 12) of SGLT2is in patients with partial lipodystrophy was conducted at our institution. The efficacy outcomes included hemoglobin A1C level, insulin dose, fasting plasma glucose level, C-peptide level, lipid profile, 24-hour urinary glucose excretion, estimated glomerular filtration rate, and blood pressure before and after 12 months of SGLT2i treatment. Results The hemoglobin A1C level decreased after SGLT2i treatment (at baseline: 9.2% ± 2.0% [77.0 ± 21.9 mmol/mol]; after 12 months: 8.4% ± 1.8% [68.0 ± 19.7 mmol/mol]; P = .028). Significant reductions were also noted in systolic (P = .011) and diastolic blood pressure (P = .013). There was a trend toward a decreased C-peptide level (P = .071). The fasting plasma glucose level, lipid level, and estimated glomerular filtration rate remained unchanged. The adverse effects included extremity pain, hypoglycemia, diabetic ketoacidosis (in a patient who was nonadherent to insulin), pancreatitis (in a patient with prior pancreatitis), and fungal infections. Conclusion SGLT2is reduced the hemoglobin A1C level in patients with partial lipodystrophy, with a similar safety profile compared with that in patients with type 2 diabetes. After individual consideration of the risks and benefits of SGLT2is, these may be considered a part of the treatment armamentarium for these rare forms of diabetes, but larger trials are needed to confirm these findings." @default.
- W4220940285 created "2022-04-03" @default.
- W4220940285 creator A5000884587 @default.
- W4220940285 creator A5020936306 @default.
- W4220940285 creator A5031833152 @default.
- W4220940285 creator A5052481238 @default.
- W4220940285 date "2022-03-01" @default.
- W4220940285 modified "2023-10-15" @default.
- W4220940285 title "Clinical effects of sodium glucose transporter type 2 inhibitors in patients with partial lipodystrophy" @default.
- W4220940285 cites W1953840628 @default.
- W4220940285 cites W2020803051 @default.
- W4220940285 cites W2061457508 @default.
- W4220940285 cites W2066961578 @default.
- W4220940285 cites W2068171948 @default.
- W4220940285 cites W2081510795 @default.
- W4220940285 cites W2084310603 @default.
- W4220940285 cites W2101344933 @default.
- W4220940285 cites W2154029700 @default.
- W4220940285 cites W2602096675 @default.
- W4220940285 cites W2794213484 @default.
- W4220940285 cites W2797973053 @default.
- W4220940285 cites W2886865853 @default.
- W4220940285 cites W2909093692 @default.
- W4220940285 cites W2995391363 @default.
- W4220940285 cites W3015945217 @default.
- W4220940285 cites W3038341420 @default.
- W4220940285 cites W3126553617 @default.
- W4220940285 cites W4211034139 @default.
- W4220940285 doi "https://doi.org/10.1016/j.eprac.2022.03.006" @default.
- W4220940285 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35301125" @default.
- W4220940285 hasPublicationYear "2022" @default.
- W4220940285 type Work @default.
- W4220940285 citedByCount "0" @default.
- W4220940285 crossrefType "journal-article" @default.
- W4220940285 hasAuthorship W4220940285A5000884587 @default.
- W4220940285 hasAuthorship W4220940285A5020936306 @default.
- W4220940285 hasAuthorship W4220940285A5031833152 @default.
- W4220940285 hasAuthorship W4220940285A5052481238 @default.
- W4220940285 hasBestOaLocation W42209402851 @default.
- W4220940285 hasConcept C126322002 @default.
- W4220940285 hasConcept C134018914 @default.
- W4220940285 hasConcept C142462285 @default.
- W4220940285 hasConcept C159641895 @default.
- W4220940285 hasConcept C197934379 @default.
- W4220940285 hasConcept C2777180221 @default.
- W4220940285 hasConcept C2777391703 @default.
- W4220940285 hasConcept C2778917026 @default.
- W4220940285 hasConcept C2779306644 @default.
- W4220940285 hasConcept C2780941825 @default.
- W4220940285 hasConcept C2781283889 @default.
- W4220940285 hasConcept C2993143319 @default.
- W4220940285 hasConcept C3013748606 @default.
- W4220940285 hasConcept C512399662 @default.
- W4220940285 hasConcept C555293320 @default.
- W4220940285 hasConcept C71924100 @default.
- W4220940285 hasConcept C90924648 @default.
- W4220940285 hasConceptScore W4220940285C126322002 @default.
- W4220940285 hasConceptScore W4220940285C134018914 @default.
- W4220940285 hasConceptScore W4220940285C142462285 @default.
- W4220940285 hasConceptScore W4220940285C159641895 @default.
- W4220940285 hasConceptScore W4220940285C197934379 @default.
- W4220940285 hasConceptScore W4220940285C2777180221 @default.
- W4220940285 hasConceptScore W4220940285C2777391703 @default.
- W4220940285 hasConceptScore W4220940285C2778917026 @default.
- W4220940285 hasConceptScore W4220940285C2779306644 @default.
- W4220940285 hasConceptScore W4220940285C2780941825 @default.
- W4220940285 hasConceptScore W4220940285C2781283889 @default.
- W4220940285 hasConceptScore W4220940285C2993143319 @default.
- W4220940285 hasConceptScore W4220940285C3013748606 @default.
- W4220940285 hasConceptScore W4220940285C512399662 @default.
- W4220940285 hasConceptScore W4220940285C555293320 @default.
- W4220940285 hasConceptScore W4220940285C71924100 @default.
- W4220940285 hasConceptScore W4220940285C90924648 @default.
- W4220940285 hasLocation W42209402851 @default.
- W4220940285 hasLocation W42209402852 @default.
- W4220940285 hasOpenAccess W4220940285 @default.
- W4220940285 hasPrimaryLocation W42209402851 @default.
- W4220940285 hasRelatedWork W138803513 @default.
- W4220940285 hasRelatedWork W1986132654 @default.
- W4220940285 hasRelatedWork W2010140898 @default.
- W4220940285 hasRelatedWork W2010484394 @default.
- W4220940285 hasRelatedWork W2032225465 @default.
- W4220940285 hasRelatedWork W2082140668 @default.
- W4220940285 hasRelatedWork W2092579885 @default.
- W4220940285 hasRelatedWork W2151350502 @default.
- W4220940285 hasRelatedWork W2410789767 @default.
- W4220940285 hasRelatedWork W4234612679 @default.
- W4220940285 isParatext "false" @default.
- W4220940285 isRetracted "false" @default.
- W4220940285 workType "article" @default.